Life Sciences Industry
51 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Patricia MAMMES
Scoop.it!

Johnson & Johnson Recalls Some Jaw Implants - Fox Business

Johnson & Johnson Recalls Some Jaw Implants - Fox Business | Life Sciences Industry | Scoop.it
Johnson & Johnson Recalls Some Jaw Implants
Fox Business
Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw, following more than a dozen cases of injury.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Pfizer Takes Lead Over Sanofi With Fast-Track Designation Of Its C. Difficile ... - Bidness ETC

Pfizer Takes Lead Over Sanofi With Fast-Track Designation Of Its C. Difficile ... - Bidness ETC | Life Sciences Industry | Scoop.it
Bidness ETC
Pfizer Takes Lead Over Sanofi With Fast-Track Designation Of Its C. Difficile ...
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

GEN | News Highlights:Pfizer, Merck & Co. Expand Cancer Combo Collaboration

GEN | News Highlights:Pfizer, Merck & Co. Expand Cancer Combo Collaboration | Life Sciences Industry | Scoop.it
New Phase Ib trial will combine Pfizer’s Xalkori® with Merck’s pembrolizumab in ALK+ advanced or metastatic NSCLC (Pfizer, Merck & Co.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Novartis' New Heart Drug Cuts Cardiovascular Death Risk By 20% - Investing.com

Novartis' New Heart Drug Cuts Cardiovascular Death Risk By 20% - Investing.com | Life Sciences Industry | Scoop.it
Novartis' New Heart Drug Cuts Cardiovascular Death Risk By 20%
Investing.com
By J.J.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

GSK recalls batches of Eye-Mo for 'noncompliance' with standards - GMA News

GSK recalls batches of Eye-Mo for 'noncompliance' with standards - GMA News | Life Sciences Industry | Scoop.it
GSK recalls batches of Eye-Mo for 'noncompliance' with standards
GMA News
Pharmaceutical firm GlaxoSmithKline is recalling several batches of its Eye-Mo Red Eyes Formula Ophthalmic Solution, the Food and Drug Administration said over the weekend.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Novartis Rises Most in Three Years on Heart-Drug Trial - Businessweek

Novartis Rises Most in Three Years on Heart-Drug Trial - Businessweek | Life Sciences Industry | Scoop.it
Reuters Novartis Rises Most in Three Years on Heart-Drug Trial Businessweek Novartis AG (NOVN) gained the most in almost three years after a study showed that an experimental heart failure drug kept more patients from dying or being hospitalized...
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

UPDATE 1-"Most exciting ever" Novartis drug points to huge sales - Reuters

UPDATE 1-"Most exciting ever" Novartis drug points to huge sales
Reuters
Novartis sees margins on LCZ696 better than for Diovan. * Shares up 3.4 percent to record high (Recasts with shares, analyst reaction, background).
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Venus Remedies ties up with Teva - The Hindu

Venus Remedies ties up with Teva - The Hindu | Life Sciences Industry | Scoop.it
Venus Remedies ties up with Teva
The Hindu
Venus Remedies has entered into a collaborative agreement with Teva, the largest manufacturer of generic drugs in the world, for anti-cancer drug in the Canadian market.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

GSK appoints new sales director - Talking Retail

GSK appoints new sales director - Talking Retail | Life Sciences Industry | Scoop.it
Talking Retail GSK appoints new sales director Talking Retail GSK said Szymankiewicz will lead sales across all retailers and channels for brands such as Sensodyne, Aquafresh, Beechams, Panadol, NiQuitin and Maxinutrition, working closely with...
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Cholesterol Drug: Sanofi and Regeneron Say New Medication Can Cut Srokes ... - Headlines & Global News

Cholesterol Drug: Sanofi and Regeneron Say New Medication Can Cut Srokes ... - Headlines & Global News | Life Sciences Industry | Scoop.it
Headlines & Global News
Cholesterol Drug: Sanofi and Regeneron Say New Medication Can Cut Srokes ...
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Bayer/Johnson & Johnson to Expand Xarelto Label Further - Zacks.com

Bayer/Johnson & Johnson to Expand Xarelto Label Further - Zacks.com | Life Sciences Industry | Scoop.it
Bayer/Johnson & Johnson to Expand Xarelto Label Further
Zacks.com
The drug is marketed by Johnson & Johnson in the U.S. and by Bayer outside the U.S.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Chugai and Roche amend business arrangements on out-licensing - The Pharma Letter

Chugai and Roche amend business arrangements on out-licensing - The Pharma Letter | Life Sciences Industry | Scoop.it
Chugai and Roche amend business arrangements on out-licensing The Pharma Letter Japanese drugmaker Chugai POharmaceutical (TYO: 4591) has amended the business arrangements with its majority (62%) share-owner Swiss pharma major Roche (ROG: SIX)...
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

EU regulators set Oct. 3 deadline for Eli Lilly, Novartis deal - Reuters

EU regulators set Oct. 3 deadline for Eli Lilly, Novartis deal
Reuters
BRUSSELS, Sept 1 (Reuters) - European Union competition regulators have until Oct. 3 to decide whether to approve U.S.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Sanofi appoints Japan exec to lead US pharma ops - FierceBiotech

Sanofi appoints Japan exec to lead US pharma ops - FierceBiotech | Life Sciences Industry | Scoop.it
Sanofi appoints Japan exec to lead US pharma ops
FierceBiotech
... > Novartis ($NVS) neurologist Dr. Donald Johns is joining Biogen Idec ($BIIB) as vice president. Johns will head the amyotrophic lateral sclerosis Innovation Hub.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Zacks.com

Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Zacks.com | Life Sciences Industry | Scoop.it
Monthly Prescribing Reference
Protalix/Pfizer's Elelyso Approved in Pediatric Patients
Zacks.com
ProtalixBioTherapeutics, Inc. (PLX - Snapshot Report) and partner Pfizer Inc.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Teva's Patent Problems Continue - Bidness ETC

Teva's Patent Problems Continue - Bidness ETC | Life Sciences Industry | Scoop.it
Bidness ETC Teva's Patent Problems Continue Bidness ETC Teva Pharmaceuticals Industries Ltd (ADR) (TEVA) is in trouble again for its multiple sclerosis (MS) injectable drug-Copaxone, as other drug manufacturers seek to launch their own generic...
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

J&J And Bristol-Myers Changing The Myeloma Drug Landscape - Bidness ETC

J&J And Bristol-Myers Changing The Myeloma Drug Landscape - Bidness ETC | Life Sciences Industry | Scoop.it
Bidness ETC
J&J And Bristol-Myers Changing The Myeloma Drug Landscape
Bidness ETC
... be signaling a shift in this market trend.
more...
No comment yet.
Rescooped by Patricia MAMMES from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

Darapladib ( GSK) Fails in SOLID-TIMI 52 Phase III trial. ESC

Darapladib ( GSK)  Fails in SOLID-TIMI 52 Phase III trial. ESC | Life Sciences Industry | Scoop.it
Cardiology | BARCELONA, Spain — After ACS, direct inhibition of lipoprotein-associated phospholipase A2 with darapladib failed to reduce the risk for coronary events when compared with placebo.
The SOLID-TIMI 52 trial included 13,026 patients (mean age, 64 years; 74.5% men) within 30 days of hospitalization with an ACS who were randomly assigned once-daily darapladib 160 mg (n=6,504) or matching placebo

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, September 1, 2014 7:05 AM

This is the second Phase III failure for Darapladib. GSK got the rights to the drug with acquisition of HGS. With the market failure of belimumab in lupus and the failure of the darapladib in two mega Phase III trials in over 27000 patients. HGS acquisition has not paid off for GSK.

Scooped by Patricia MAMMES
Scoop.it!

Novartis Japan admits concealing drug side effects - Business Insider

Novartis Japan admits concealing drug side effects - Business Insider | Life Sciences Industry | Scoop.it
Business Insider Novartis Japan admits concealing drug side effects Business Insider Tokyo (AFP) - The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its...
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

EU regulators set Oct. 3 deadline for Eli Lilly, Novartis deal - Reuters UK

EU regulators set Oct. 3 deadline for Eli Lilly, Novartis deal
Reuters UK
BRUSSELS, Sept 1 (Reuters) - European Union competition regulators have until Oct. 3 to decide whether to approve U.S.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Exclusive: 'Back to normal' for AstraZeneca CEO, despite Pfizer rumors

Exclusive: 'Back to normal' for AstraZeneca CEO, despite Pfizer rumors | Life Sciences Industry | Scoop.it
BARCELONA (Reuters) - Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Cipla Poses Strong Competition For GSK And Gilead

Cipla Poses Strong Competition For GSK And Gilead | Life Sciences Industry | Scoop.it
GlaxoSmithKline plc (ADR) (NYSE:GSK), Cipla Ltd (NYSE:CIPLA), Gilead Sciences, Inc. (NASDAQ:GILD): Cipla, an Indian generic-drug manufacturer, is planning to launch generic versions of asthma and HIV drugs in the US.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Boston Scientific completes Bayer Interventional deal - Minneapolis Star Tribune

Boston Scientific completes Bayer Interventional deal - Minneapolis Star Tribune | Life Sciences Industry | Scoop.it
Boston Scientific completes Bayer Interventional deal
Minneapolis Star Tribune
Boston Scientific has said Bayer's 350 Minnesota employees are not expected to lose their jobs as part of the deal.
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

Bayer plans $100 million project in Berkeley — maybe - Pittsburgh Business Times

Bayer plans $100 million project in Berkeley — maybe - Pittsburgh Business Times | Life Sciences Industry | Scoop.it
Bayer plans $100 million project in Berkeley — maybe Pittsburgh Business Times Bayer HealthCare Pharmaceuticals could spend $100 million to build a product testing facility and raze three buildings in Berkeley, but the drug developer said a final...
more...
No comment yet.
Scooped by Patricia MAMMES
Scoop.it!

3 Reasons Eli Lilly & Co.'s Stock Could Rise - Motley Fool

3 Reasons Eli Lilly & Co.'s Stock Could Rise - Motley Fool | Life Sciences Industry | Scoop.it
Bidness ETC
3 Reasons Eli Lilly & Co.'s Stock Could Rise
Motley Fool
Eli Lilly & Co. (NYSE: LLY ) has faced some tough times with the loss of patent protection on a handful of its best-selling products.
more...
No comment yet.